Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B? (Q37863921)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21482486%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

review article

1 reference

title

Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21482486%20AND%20SRC:MED&resulttype=core&format=json

Caterina Giovanna Valentini

28 January 2020

main subject

aspergillosis

0 references

invasive aspergillosis

1 reference

1 reference

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21482486%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21482486%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Pagano L

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21482486%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Caira M

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21482486%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

publication date

1 February 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21482486%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

published in

Journal of Chemotherapy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21482486%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21482486%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21482486%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

5-8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21482486%20AND%20SRC:MED&resulttype=core&format=json

Factors associated with overall and attributable mortality in invasive aspergillosis

28 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

Invasive Aspergillosis in patients with acute leukemia: update on morbidity and mortality--SEIFEM-C Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

In vitro activity (MIC and MFC) of voriconazole, amphotericin B, and itraconazole against 192 filamentous fungi: the GISIA-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

New dosing strategies for liposomal amphotericin B in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

Risk factors for breakthrough invasive fungal infection during secondary prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.1.5

21 January 2018

Identifiers

DOI

10.1179/JOC.2011.23.1.5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21482486%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21482486%20AND%20SRC:MED&resulttype=core&format=json